Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the second quarter ended June 30, 2009.

Total revenue for the second quarter of 2009 was $3.5 million, with a net loss of $22.9 million, including non-cash charges of $21.0 million related to the financing completed in April. Loss from operations was $1.9 million for the second quarter and $10.2 million for the first half of 2009. As of June 30, 2009, cash, cash equivalents and marketable securities totaled $7.3 million, with no debt outstanding.

"In the second quarter, we completed the initial closing of a tranched financing of up to $43.5 million with a syndicate of experienced life science investors. We also presented positive new data on all three of our Phase 2 voreloxin studies at ASCO," said Daniel Swisher, Chief Executive Officer of Sunesis. "As we finish enrollment of both of our Phase 2 studies in AML, we are actively planning for an End-of-Phase 2 meeting later this year with the FDA to gain concurrence on our AML registration strategy."

Recent Highlights

  • In April, Sunesis completed a $10.0 million initial closing of a tranched private placement of up to $43.5 million. The private placement contemplates the sale of up to $15.0 million of units of convertible preferred stock and common stock warrants and up to $28.5 million in common stock to accredited investors, including certain members of management. In the initial closing, $10.0 million of units were sold, resulting in net proceeds of $8.8 million. The remaining units may be issued by Sunesis upon the satisfaction of a clinical milestone and Sunesis' common stock trading above a specified floor price or upon approval by a majority
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), the ... diseases, today announced that it will host its First ... Thursday, August 13, 2015 at 4:30 p.m. Eastern Time. ... release of fiscal 2016 first quarter results.  A recorded ... hours after the call at the Investor Relations portion ...
(Date:8/3/2015)... YORK , August 3, 2015 ... Market Study on 3D Cell Culture: Asia ... by Persistence Market Research, the global 3D cell culture market was ... expected to expand at a CAGR of 29.1% to ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm ... quantification of partially hydrolyzed gluten in foods, has been accepted by AOAC International ... “Partially Hydrolyzed Gluten in Fermented Cereal-Based Products by R5 Competitive ELISA,” based on ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... Research,Institute (BBRI) in Watertown, Massachusetts, was once again ... by Moody,s Investor Services, affirming,the Institute,s financial stability ... overall precarious economy that have left some similar,organizations ... confirmation,of our financial health," says BBRI Director and ...
... -- Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... conference call on Monday, March 31, 2008 at 9:00 ... ended December 31, 2007 financial,results and provide an update ... call, please dial 1-877-407-4018 (USA) or,1-201- 689-8471 (international). A ...
... Inc. (OTC Bulletin Board: WGBS), a leading ... and stem cell,research systems, today announced the ... company,s SmartSlide(TM) Micro-Incubation System with,Labtech International Limited ... in,France. The distributor agreement covers WaferGen,s entire ...
Cached Biology Technology:Boston Biomedical Research Institute Maintains Baa3 Rating from Moody's 2Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 2WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 3WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 4WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France 5
(Date:7/27/2015)... JOSE, Calif. , July 27, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... ® touchscreen solution for its stylish smartwatch. ... for its proven reliability, low power and highly ... a wet finger. Huawei designers also required a ...
(Date:7/23/2015)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... second quarter ended June 30, 2015.  Revenue ... decrease of 33% compared to $6.8 million in the same ... 2015 was $0.3 million, or $0.01 per diluted share, which ... the same period a year ago.  Lower ...
(Date:7/21/2015)... Today, ZTE announced its Android smartphone Axon, featuring FPC,s ... in 2015 that relate to sales of FPC1025 for this smartphone ... MSEK for 2015. Jörgen Lantto, CEO of FPC, comments: ... China and we are proud that ... Axon , its first smartphone ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... When a portion of a zebrafish's heart is removed, ... that forms in the wound and the protective cell ... functional new heart tissue, Duke University Medical Center scientists ... growth factors facilitate the interaction between the cell mass ...
... the Gladstone Institute of Virology and Immunology (GIVI) have identified ... acts against HIV, a finding that may lead to new ... published today, Oct. 2, 2006, in Proceedings of the National ... in the laboratory of GIVI Director Warner C. Greene, MD, ...
... high tech tools, researchers have identified three proteins that ... 20 months before the rejection occurred. , Lung transplant ... about 45% over five years, said lead investigator and ... to predict which transplants will fail, and when signs ...
Cached Biology News:Key to zebrafish heart regeneration uncovered 2Key to zebrafish heart regeneration uncovered 3Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
... 96/384 workstation offers precise 96 and 384-well ... Utilizing 100ul and 200ul disposable tips, the ... accuracy and precision across a volume range ... includes two positions that enable indexing into ...
... reduce the chance of error. Thats the ... using Beckman Coulters extensive experience in laboratory ... the CEQ 8000 is a fully automated ... the capillary array with a patented linear ...
... The AquaMax DW4 liquid handling system from ... washing all in one instrument. The system ... dispensing and plate washing96-, 384- and 1536-welland ... washing. AquaMax DW4 has been optimized to ...
... to identify over 150 peptide modifications ... isoforms, protein subsets, and suppress false ... associations and relationships easily. The software ... relative protein expression analysis for discovery ...
Biology Products: